AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

FDA seeking 'aggressive' adoption of AI . The FDA announced an "aggressive timeline" to deploy artificial intelligence ...

Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...

Jeremy Walsh, who was recently named as the FDA's first-ever AI officer, has reportedly led the discussions with OpenAI, but so far, "no contract has been signed." 'Broader trend of AI adoption in ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Drug services firms are no exception ... says the CDMO industry isn’t a leader in AI adoption or in developing innovative AI technologies. “Sometimes, it is for a good reason.

The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.